Canton Strategic Holdings (CNTN) Change in Accured Expenses (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly Change in Accured Expenses came in at -$1.5 million in Q1 2026, down 22752.21% YoY from N/an in Q1 2025, and down 196.73% on a QoQ basis from $1.5 million in Q4 2025.
Analysis
Canton Strategic Holdings (CNTN) Change in Accured Expenses (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of Change in Accured Expenses data on file, last reported at -$1.5 million in Q1 2026.
- Quarterly Change in Accured Expenses fell 22752.21% year-over-year to -$1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$378695.0 (down 147.91% YoY) and the FY2025 annual result came in at $1.1 million, up 156.55% from the prior year.
- Change in Accured Expenses fell to -$1.5 million in Q1 2026, from $1.5 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $1.5 million in Q4 2025 to a low of -$1.5 million in Q1 2026.
- A 5-year average of $36530.7 and a median of -$6376.0 in 2025 frame the typical range for Change in Accured Expenses.
- Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 6658.29% — and 2026, when it tumbled 22752.21%.
- Tracing CNTN's Change in Accured Expenses over 5 years: stood at $10597.0 in 2022, then soared by 6658.29% to $716176.0 in 2023, then plunged by 106.25% to -$44774.0 in 2024, then surged by 3464.2% to $1.5 million in 2025, then plunged by 196.73% to -$1.5 million in 2026.
- The last three Change in Accured Expenses figures came in at -$1.5 million (Q1 2026), $1.5 million (Q4 2025), and -$368137.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | 1.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.93 Mn |
| Mar 31, 2026 | -1.46 Mn |
| Dec 31, 2025 | 1.51 Mn |
| Sep 30, 2025 | -208,336.00 |
| Jun 30, 2025 | -219,588.00 |
| Mar 31, 2025 | -6,376.00 |
| Dec 31, 2024 | -44,774.00 |
| Sep 30, 2024 | 789,628.00 |
| Jun 30, 2024 | 51,935.00 |
| Mar 31, 2024 | -378,942.00 |
| Dec 31, 2023 | 716,176.00 |
| Sep 30, 2023 | 122,424.00 |
| Jun 30, 2023 | -174,351.00 |
| Mar 31, 2023 | 51,752.00 |
| Dec 31, 2022 | 10,597.00 |
| Sep 30, 2022 | -6,073.00 |
| Jun 30, 2022 | -32,941.00 |
| Mar 31, 2022 | -99,338.00 |
| Dec 31, 2021 | 13,362.00 |
| Sep 30, 2021 | 157,551.00 |